-$0.95 Earnings Per Share Expected for Five Prime Therapeutics Inc (NASDAQ:FPRX) This Quarter
Analysts expect Five Prime Therapeutics Inc (NASDAQ:FPRX) to announce ($0.95) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Five Prime Therapeutics’ earnings, with estimates ranging from ($1.11) to ($0.72). Five Prime Therapeutics posted earnings of ($1.37) per share in the same quarter last year, which suggests a positive year over year growth rate of 30.7%. The company is scheduled to report its next earnings report on Tuesday, November 5th.
On average, analysts expect that Five Prime Therapeutics will report full year earnings of ($3.91) per share for the current year, with EPS estimates ranging from ($4.27) to ($3.65). For the next fiscal year, analysts anticipate that the company will report earnings of ($2.76) per share, with EPS estimates ranging from ($3.95) to ($1.79). Zacks’ earnings per share calculations are an average based on a survey of sell-side research firms that cover Five Prime Therapeutics.
Five Prime Therapeutics (NASDAQ:FPRX) last released its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.99) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.09). Five Prime Therapeutics had a negative net margin of 842.84% and a negative return on equity of 62.13%. The firm had revenue of $3.33 million during the quarter, compared to analysts’ expectations of $5.53 million.
Institutional investors and hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP increased its position in Five Prime Therapeutics by 5.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,484,178 shares of the biotechnology company’s stock valued at $13,803,000 after buying an additional 71,001 shares in the last quarter. BNP Paribas Arbitrage SA boosted its holdings in Five Prime Therapeutics by 1,929.9% in the first quarter. BNP Paribas Arbitrage SA now owns 7,328 shares of the biotechnology company’s stock worth $98,000 after acquiring an additional 6,967 shares in the last quarter. Alps Advisors Inc. boosted its holdings in Five Prime Therapeutics by 4.5% in the first quarter. Alps Advisors Inc. now owns 85,663 shares of the biotechnology company’s stock worth $1,148,000 after acquiring an additional 3,707 shares in the last quarter. Acadian Asset Management LLC bought a new stake in Five Prime Therapeutics in the first quarter worth $1,158,000. Finally, DekaBank Deutsche Girozentrale grew its stake in shares of Five Prime Therapeutics by 2,393.0% in the first quarter. DekaBank Deutsche Girozentrale now owns 284,200 shares of the biotechnology company’s stock worth $4,019,000 after acquiring an additional 272,800 shares during the last quarter. 74.31% of the stock is currently owned by hedge funds and other institutional investors.
FPRX stock traded up $0.19 during midday trading on Friday, hitting $6.30. The stock had a trading volume of 261,600 shares, compared to its average volume of 368,109. The firm has a market cap of $231.71 million, a price-to-earnings ratio of -1.53 and a beta of 2.59. The business has a 50-day moving average of $5.48 and a two-hundred day moving average of $8.61. Five Prime Therapeutics has a 52-week low of $4.89 and a 52-week high of $16.00. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.87 and a quick ratio of 6.87.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Featured Story: What is Compound Interest?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.